ATNM
Actinium Pharmaceuticals, Inc.
0.98
400 x undefined
1200 x 0.99
bid
ask
-
0.00
0.08%
10:16 AM
timesize
| Ytd | -27.81% | |
| 1y | -31.34% |
0.98
day range
0.99
0.94
52 week range
1.89
| Open | 0.97 | Prev Close | 0.98 | Low | 0.98 | High | 0.99 | Mkt Cap | 30.80M |
| Vol | 10.12K | Avg Vol | 182.83K | EPS | -0.76 | P/E | N/A | Forward P/E | -1.77 |
| Beta | 0.15 | Short Ratio | 5.72 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.15 | 200-d Avg | 1.29 | 1yr Est | 5.00 |
| Income Statement | |||
| Operating Expenses | 5.90M | ||
| Research and Development Expense | 4.20M | ||
| Selling, General and Administrative Expense | 1.70M | ||
| Operating Income | -5.90M | ||
| Net Income | -5.52M | ||
| Net Income Common Stock | -5.52M | ||
| Net Income Common Stock (USD) | -5.52M | ||
| Consolidated Income | -5.52M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -5.52M | ||
| Earning Before Interest & Taxes (USD) | -5.52M | ||
| Weighted Average Shares | 31.24M | ||
| Weighted Average Shares Diluted | 31.24M | ||
| Balance Sheet | |||
| Cash and Equivalents | 42.13M | ||
| Cash and Equivalents (USD) | 42.13M | ||
| Investments | 337.00K | ||
| Investments Non-Current | 337.00K | ||
| Current Assets | 43.26M | ||
| Property, Plant & Equipment Net | 1.84M | ||
| Total Assets | 45.44M | ||
| Debt Current | 734.00K | ||
| Total Debt | 1.52M | ||
| Current Liabilities | 7.35M | ||
| Debt Non-Current | 785.00K | ||
| Total Liabilities | 43.13M | ||
| Accumulated Retained Earnings (Deficit) | -415.23M | ||
| Accumulated Other Comprehensive Income | -39.00K | ||
| Shareholders Equity | 2.30M | ||
| Shareholders Equity (USD) | 2.30M | ||
| Assets Non-Current | 2.18M | ||
| Total Debt (USD) | 1.52M | ||
| Deferred Revenue | 35.00M | ||
| Liabilities Non-Current | 35.78M | ||
| Trade and Non-Trade Payables | 6.62M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 220.00K | ||
| Net Cash Flow from Financing | -3.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -5.86M | ||
| Capital Expenditure | -2.00K | ||
| Issuance (Repayment) of Debt Securities | -3.00K | ||
| Net Cash Flow from Investing | -2.00K | ||
| Net Cash Flow from Operations | -5.87M | ||
| Effect of Exchange Rate Changes on Cash | 11.00K | ||
| Share Based Compensation | 11.00K | ||